Citations

Clear

1446 citation(s) found for "Howard, F".

Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates With Hemodynamics and Is Consistent With REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial
Lachant, Daniel , Osterhout, Robin , Chakinala, Murali M. , Franco, Verónica , McConnell, J.W. , Rahaghi, Franck , Sood, Namita , Spikes, Leslie , Benza, R.L., Channick, Richard N. , McLaughlin, Vallerie V. , Zamanian, R.T., Roscigno, R.F., Mottola, David, Parsley, E., Cravets, Matt , Bruey, Jean Marie, Zisman, Lawrence S. , White, R.J., Osterhout, Robin E. , Sahay, Sandeep , Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Ghofrani, Hossein Ardeschir , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier , White, R. James

Mayo Clinic

D109. NOW WE GOT BAD BLOOD: RSF/PC JOINT SESSION ON PULMONARY VASCULAR DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7475-A7475

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7475 Get It

TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve With Treatment
Osterhout, Robin , Channick, Richard N. , McLaughlin, Vallerie V. , Vachiéry, Jean‐Luc , Roscigno, R.F., Mottola, David, Sitapara, Ravikumar , Aranda, R., Zisman, Lawrence S. , Bruey, Jean Marie, Zamanian, Roham T. , Ghofrani, Hossein Ardeschir , Osterhout, Robin E. , Benza, Raymond L. , Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier

Mayo Clinic

D105. BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7383-A7383

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7383 Get It

Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, Ronald , Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard N. , McLaughlin, Vallerie V. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Sitbon, Olivier , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B., Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Ghofrani, Hossein Ardeschir

Mayo Clinic

A14. BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1011-A1011

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1011 Get It

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2
Bryce, Alan H. , Crawford, E. David , Beltran, Himisha , Petrylak, Daniel P. , Armstrong, Andrew J. , Boike, Thomas , Calais, Jérémie , Chapin, Brian F. , Cookson, Michael S. , Davis, John W. , Dorff, Tanya B. , Eggener, Scott E. , Feng, Felix Y. , Higano, Celestia S. , Poage, Wendy, Scher, Howard I. , Sieber, Paul , Srinivas, Sandy, Zhang, Tian , Koo, Phillip J. , Beltran, Himisha , Cooperberg, Matthew R , Antonarakis, Emmanuel S , Aparicio, Ana M , Calais, Jeremie , Morris, Michael J , Scher, Howard I , Bryce, Alan H , Armstrong, Andrew J , Agarwal, Neeraj , Hussain, Maha , Shore, Neal D. , Spratt, Daniel E. , Tagawa, Scott T. , Carducci, Michael A. , Gleave, Martin , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, Michael J. , Murray, Katie S. , Rettig, Matthew B. , Sartor, Oliver , Small, Eric J. , Yu, Evan Y

Mayo Clinic

JU Open Plus | April 15, 2024 | Volume: 2 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000138 | PMID 38774467 Get It

Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature. Materials and Methods: The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators. Results: This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA1/2 mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)–positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-BRCA1/2 mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies. Conclusions: The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1
Crawford, E. David , Beltran, Himisha , Petrylak, Daniel P. , Armstrong, Andrew J. , Boike, Thomas , Calais, Jérémie , Chapin, Brian F. , Cookson, Michael S. , Davis, John W. , Dorff, Tanya B. , Eggener, Scott E. , Feng, Felix Y. , Higano, Celestia S. , Poage, Wendy, Scher, Howard I. , Sieber, Paul , Srinivas, Sandy, Zhang, Tian , Koo, Phillip J. , Antonarakis, Emmanuel S , Aparicio, Ana M , Calais, Jeremie , Scher, Howard I , Armstrong, Andrew J , Bryce, Alan H. , Hussain, Maha , Agarwal, Neeraj , Cooperberg, Matthew R , Shore, Neal D. , Spratt, Daniel E. , Tagawa, Scott T. , Carducci, Michael A. , Gleave, Martin , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, Michael J. , Murray, Katie S. , Rettig, Matthew B. , Sartor, Oliver , Small, Eric J. , Yu, Evan Y

Mayo Clinic

JU Open Plus | April 15, 2024 | Volume: 2 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000137 | PMID 38774466 Get It

Purpose: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous condition encompassing a range of clinical presentations. As new approaches have expanded management options, clinicians are left with myriad questions and controversies regarding the optimal individualized management of CSPC. Materials and Methods: The US Prostate Cancer Conference (USPCC) multidisciplinary panel was assembled to address the challenges of prostate cancer management. The first annual USPCC meeting included experts in urology, medical oncology, radiation oncology, and nuclear medicine. USPCC co-chairs and session moderators identified key areas of controversy and uncertainty in prostate cancer management and organized the sessions with multidisciplinary presentations and discussion. Throughout the meeting, experts responded to questions prepared by chairs and moderators to identify areas of agreement and controversy. Results: The USPCC panel discussion and question responses for CSPC-related topics are presented. Key advances in CSPC management endorsed by USPCC experts included the development and clinical utilization of gene expression classifiers and artificial intelligence (AI) models for risk stratification and treatment selection in specific patient populations, the use of advanced imaging modalities in patients with clinically localized unfavorable intermediate or high-risk disease and those with biochemical recurrence, recommendations of doublet or triplet therapy for metastatic CSPC (mCSPC), and consideration of prostate and/or metastasis-directed radiation therapy in select patients with mCSPC. Conclusions: CSPC is a diverse disease with many therapeutic options and the potential for adverse outcomes associated with either undertreatment or overtreatment. Future studies are needed to validate and clinically integrate novel technologies, including genomics, AI, and advanced imaging, to optimize outcomes among patients with CSPC.
Interrater Reliability of the Multidomain Impairment Rating (MIR) Scale in Frontotemporal Lobar Degeneration: Data from the ALLFTD Consortium (P3-9.005)
Miyagawa, Toji , Merrilees, Jennifer , Syrjanen, Jeremy A. , Brushaber, Danielle , Fields, Julie A. , Forsberg, Leah K. , Heuer, Hilary W. , Huey, Edward D. , Kornak, John , Boxer, Adam L. , Rosen, Howard, Kremers, Walter K. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205322 Get It

Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M. , Berg, David D. , Bohula, Erin A. , Baird-Zars, Vivian M., Barsness, Gregory W. , Chaudhry, Sunit‐Preet , Chonde, Meshe , Cooper, Howard A., Ginder, Curtis , Kontos, Michael C. , Miller, P. Elliott , Newby, L. Kristin , O’Brien, Connor , Park, Jeong‐Gun , Pierce, Matthew , Pisani, Barbara , Teuteberg, Jeffrey J. , Katz, Jason N. , Chonde, Meshe D , Miller, P Elliott , Newby, L Kristin , O'Brien, Connor G , Park, Jeong-Gun , Pierce, Matthew J , Pisani, Barbara A , Potter, Brian J , Teuteberg, Jeffrey J , Katz, Jason N , van Diepen, Sean , Morrow, David A , Bohula, Erin A , Berg, David , Patel, Siddharth M , Ginder, Curtis , Jentzer, Jacob C. , Shah, Kevin S , Diepen, Sean van , Morrow, David A.

Mayo Clinic

Circulation: Heart Failure | April 8, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circheartfailure.124.011736 | PMID 38587438 Get It

BACKGROUND: Associations of early changes in vasoactive support with cardiogenic shock (CS) mortality remain incompletely defined. METHODS: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units. Patients admitted with CS (2018–2023) had vasoactive dosing assessed at 4 and 24 hours from cardiac intensive care unit admission and quantified by the vasoactive-inotropic score (VIS). Prognostic associations of VIS at both time points, as well as change in VIS from 4 to 24 hours, were examined. Interaction testing was performed based on mechanical circulatory support status. RESULTS: Among 3665 patients, 82% had a change in VIS <10, with 7% and 11% having a ≥10-point increase and decrease from 4 to 24 hours, respectively. The 4 and 24-hour VIS were each associated with cardiac intensive care unit mortality (13%–45% and 11%–73% for VIS <10 to ≥40, respectively; P trend <0.0001 for each). Stratifying by the 4-hour VIS, changes in VIS from 4 to 24 hours had a graded association with mortality, ranging from a 2- to >4-fold difference in mortality comparing those with a ≥10-point increase to ≥10-point decrease in VIS ( P trend <0.0001). The change in VIS alone provided good discrimination of cardiac intensive care unit mortality (C-statistic, 0.72 [95% CI, 0.70–0.75]) and improved discrimination of the 24-hour Sequential Organ Failure Assessment score (0.72 [95% CI, 0.69–0.74] to 0.76 [95% CI, 0.74–0.78]) and the clinician-assessed Society for Cardiovascular Angiography and Interventions shock stage (0.72 [95% CI, 0.70–0.74] to 0.77 [95% CI, 0.75–0.79]). Although present in both groups, the mortality risk associated with VIS was attenuated in patients managed with versus without mechanical circulatory support (odds ratio per 10-point higher 24-hour VIS, 1.36 [95% CI, 1.23–1.49] versus 1.84 [95% CI, 1.69–2.01]; P interaction <0.0001). CONCLUSIONS: Early changes in the magnitude of vasoactive support in CS are associated with a gradient of risk for mortality. These data suggest that early VIS trajectory may improve CS prognostication, with the potential to be leveraged for clinical decision-making and research applications in CS.
5-Year Follow-Up of a Physician Performance Feedback Report Intervention to Reduce Overuse and Excess Cost: A National Cohort Study
Walsh, Christi, Stasko, Thomas, Vidimos, Allison T. , Leshin, Barry, Billingsley, Elizabeth M. , Coldiron, Brett M., Bennett, Richard G. , Marks, Victor J., Otley, Clark C. , Rogers, Howard W., Goldman, Glenn D., Albertini, John G., Makary, Martin A. , Dun, Chen , Hicks, Caitlin W.

Mayo Clinic

Dermatologic Surgery | April 5, 2024 | Volume: 50 | Issue: 6 | Pages: 558-564

10.1097/dss.0000000000004165 | PMID 38578837 Get It

BACKGROUND Mohs micrographic surgery efficiently treats skin cancer through staged resection, but surgeons' varying resection rates may lead to higher medical costs. OBJECTIVE To evaluate the cost savings associated with a quality improvement. MATERIALS AND METHODS The authors conducted a retrospective cohort study using 100% Medicare fee-for-service claims data to identify the change of mean stages per case for head/neck (HN) and trunk/extremity (TE) lesions before and after the quality improvement intervention from 2016 to 2021. They evaluated surgeon-level change in mean stages per case between the intervention and control groups, as well as the cost savings to Medicare over the same time period. RESULTS A total of 2,014 surgeons performed Mohs procedures on HN lesions. Among outlier surgeons who were notified, 31 surgeons (94%) for HN and 24 surgeons (89%) for TE reduced their mean stages per case with a median reduction of 0.16 and 0.21 stages, respectively. Reductions were also observed among outlier surgeons who were not notified, reducing their mean stages per case by 0.1 and 0.15 stages, respectively. The associated total 5-year savings after the intervention was 92 million USD. CONCLUSION The implementation of this physician-led benchmarking model was associated with broad reductions of physician utilization and significant cost savings.
Embryonal sarcoma of the liver in pediatric and young adult patients: A report from Children’s Oncology Group study ARST0332
Spunt, Sheri L. , Xue, Wei , Gao, Zhengya, Dixon, Andrea Hayes, Million, Lynn , Polites, Stephanie F. , Vasudevan, Sanjeev A. , Kao, Simon C. , McCarville, M. Beth , Barkauskas, Donald A. , Cai, Zhongjie, Cost, Carrye , Weiss, Aaron R , Spunt, Sheri L , Kao, Simon C , Parham, David M. , Mascarenhas, Leo , Weiss, Aaron R.

Mayo Clinic

Cancer | April 3, 2024 | Volume: 130 | Issue: 15 | Pages: 2683-2693

10.1002/cncr.35305 | PMID 38567652 Get It

AbstractBackgroundEmbryonal sarcoma of the liver (ESL) is a rare mesenchymal tumor most common in childhood; the optimal treatment approach is uncertain. The clinical features and outcomes of patients with ESL enrolled in a Children’s Oncology Group (COG) clinical trial that evaluated a risk‐based strategy for treating soft tissue sarcomas in patients aged <30 years were evaluated.MethodsThis subset analysis included patients with ESL enrolled in COG study ARST0332. Central review of records, pathology, and imaging confirmed the diagnosis, presenting features, and surgery extent and complications. All patients received dose‐intensive ifosfamide/doxorubicin chemotherapy, with cycle timing dependent on surgery and radiotherapy. Tumor resection occurred before study entry or after four cycles of chemotherapy; radiotherapy for residual tumor was optional.ResultsThirty‐nine eligible/evaluable patients with ESL were analyzed. All tumors were >10 cm in diameter; four were metastatic. Tumor resection was performed upfront in 23 and delayed in 16. Positive surgical margins (n = 6) and intraoperative tumor rupture (n = 6) occurred only in upfront resections. Eight patients received radiotherapy. Estimated 5‐year event‐free and overall survival were 79% (95% confidence interval [CI], 65%–93%) and 95% (95% CI, 87%–100%), respectively. Positive margins increased the local recurrence risk. One of 13 patients with documented hemorrhagic ascites and/or tumor rupture developed extrahepatic intra‐abdominal tumor recurrence.ConclusionsThe treatment strategy used in ARST0332 achieved favorable outcomes for patients with ESL despite a substantial proportion having high‐risk disease features. Deferring tumor resection until after neoadjuvant chemotherapy may decrease the risk of intraoperative tumor rupture and improve the likelihood of adequate surgical margins.